Skip to main content
    N

    Novartis AG ADR (NVS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $160.21
    -0.29 (-0.18%)

    Market Cap: $303.12B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Novartis AG ADR (NVS) Financials: Revenue, Profit and Cash Flow

    Updated Oct 27, 2026. Financial statements from company filings, amounts in US dollars.

    Novartis AG ADR reported revenue of $54.81B for the fiscal year ended Dec 31, 2025, up 6.0% from the year before. That year, net income was $14.06B with a net margin of 25.6%, operating cash flow was $19.24B and free cash flow was $17.69B. The quarter ended Sep 30, 2026 had revenue of $15.03B and net income of $1.20B.

    Revenue and Margins

    The operating margin was 31.2% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $49.44B, a compound annual rate of 1.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$54.81B+6.0%75.0%31.2%25.6%
    Dec 2024$51.72B+10.8%75.2%28.1%23.1%
    Dec 2023$46.66B+7.4%73.3%20.9%31.8%
    Dec 2022$43.46B-1.2%73.4%18.3%16.0%
    Dec 2021$43.97B-11.9%73.3%22.9%54.6%
    Dec 2020$49.90B+2.5%69.7%20.3%16.2%
    Dec 2019$48.68B+5.6%70.4%18.7%24.1%
    Dec 2018$46.10B+6.2%68.5%18.2%27.4%
    Dec 2017$43.40B-12.2%68.6%20.0%17.7%
    Dec 2016$49.44BN/A64.6%16.7%13.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 17.8% from the year before. In the quarter ended Sep 2026, net income fell 69.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$54.81B$51.72B$46.66B$43.46B$43.97B$49.90B$48.68B$46.10B$43.40B$49.44B
    Cost of revenue$13.69B$12.83B$12.47B$11.58B$11.73B$15.12B$14.43B$14.51B$13.63B$17.52B
    Gross profit$41.12B$38.90B$34.19B$31.88B$32.24B$34.78B$34.25B$31.59B$29.77B$31.92B
    Research and development$10.74B$10.02B$11.37B$9.17B$8.64B$8.98B$9.40B$8.49B$8.39B$9.04B
    Operating income$17.07B$14.54B$9.77B$7.95B$10.06B$10.15B$9.09B$8.40B$8.70B$8.27B
    Net income$14.06B$11.94B$14.85B$6.96B$24.02B$8.07B$11.73B$12.61B$7.70B$6.71B
    EBITDA$22.99B$20.71B$18.25B$14.68B$30.91B$17.21B$15.62B$20.24B$14.59B$14.57B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    Revenue$15.03B$14.42B$13.52B$13.33B$14.36B$14.36B$14.84B$13.62B$13.56B$13.17B$12.87B$12.12B
    Gross profit$11.42B$10.74B$10.06B$9.79B$10.82B$10.82B$11.51B$10.39B$10.23B$9.94B$9.70B$9.02B
    Operating income$1.84B$4.74B$4.24B$3.52B$4.50B$4.50B$4.86B$4.66B$3.53B$3.63B$4.01B$3.37B
    Net income$1.20B$3.27B$3.16B$2.41B$3.93B$3.93B$4.04B$3.61B$2.82B$3.19B$3.25B$2.69B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $33.72B exceeded cash and equivalents by $22.28B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$115.57B$102.25B$99.94B$117.45B$131.79B$132.19B$118.41B$145.56B$133.08B$130.12B
    Current assets$30.46B$29.70B$30.48B$36.91B$45.72B$29.67B$29.50B$35.56B$28.21B$24.93B
    Cash and equivalents$11.44B$11.46B$13.39B$7.52B$12.41B$9.66B$11.11B$13.27B$8.86B$7.01B
    Total liabilities$69.02B$58.12B$53.20B$58.03B$63.97B$75.52B$62.86B$66.87B$58.85B$55.23B
    Short-term debt$5.78B$8.32B$6.31B$6.13B$6.50B$9.88B$7.09B$9.62B$5.20B$8.05B
    Long-term debt$27.93B$21.37B$18.44B$20.24B$22.90B$26.26B$20.35B$22.47B$23.22B$17.90B
    Shareholder equity$46.13B$44.05B$46.67B$59.34B$67.66B$56.60B$55.47B$78.61B$74.17B$74.83B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    Total assets$117.15B$122.03B$118.53B$115.57B$107.29B$107.29B$104.39B$99.94B$102.25B$103.52B$97.50B$94.33B
    Total liabilities$79.58B$80.09B$79.61B$69.02B$62.54B$62.54B$62.34B$61.49B$58.12B$60.08B$55.60B$54.58B
    Cash and equivalents$8.87B$7.62B$6.88B$11.44B$9.56B$9.56B$6.66B$7.07B$11.46B$13.61B$7.90B$9.47B
    Shareholder equity$37.23B$41.54B$38.51B$46.13B$44.33B$44.33B$41.98B$38.37B$44.05B$43.32B$41.73B$39.67B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 91.9% of operating cash flow. Dividends came to 44.4% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$19.24B$17.62B$14.46B$14.24B$15.07B$13.65B$13.63B$14.27B$12.62B$11.47B
    Capital expenditures$1.56B$3.81B$2.75B$2.67B$2.97B$2.58B$2.26B$3.35B$2.75B$2.88B
    Free cash flow$17.69B$13.80B$11.71B$11.56B$12.10B$11.06B$11.37B$10.92B$9.88B$8.60B
    Dividends paid$7.86B$7.62B$7.25B$7.51B$7.37B$6.99B$6.64B$6.97B$6.50B$6.47B
    Investing cash flow-$4.90B-$7.51B$5.60B$1.47B$4.21B-$13.18B-$2.23B-$5.59B-$3.12B-$3.44B
    Financing cash flow-$14.94B-$11.74B-$14.28B-$20.56B-$16.26B-$2.21B-$13.63B-$4.24B-$7.73B-$5.31B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    Operating cash flow$5.50B$5.89B$3.68B$2.25B$6.57B$6.57B$6.66B$3.65B$4.19B$6.29B$4.88B$2.27B
    Capital expenditures$742.00M$321.07M$807.00M$610.90M$831.00M$831.00M$558.00M$1.49B$1.13B$799.00M$728.00M$1.16B
    Free cash flow$4.76B$5.57B$2.87B$1.64B$5.74B$5.74B$6.11B$2.15B$3.06B$5.49B$4.15B$1.11B
    Last 12 quarters

    Frequently Asked Questions About NVS

    What is Novartis AG ADR's annual revenue?

    Novartis AG ADR reported revenue of $54.81B for the fiscal year ended Dec 31, 2025.

    How fast is Novartis AG ADR's revenue growing?

    Revenue was up 6.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.0%.

    Is Novartis AG ADR profitable?

    Yes. Novartis AG ADR reported net income of $14.06B for the fiscal year ended Dec 31, 2025, with a net margin of 25.6%.

    How much free cash flow does NVS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $19.24B minus capital expenditures of $1.56B produced free cash flow of $17.69B.

    How much debt does Novartis AG ADR have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $27.93B, short-term debt of $5.78B and cash and equivalents of $11.44B.